Case Report

Persistent Lymphadenopathy due to IgG4-Related Disease

Benjamin Smith and Matthew B. Carroll

81st Medical Group Hospital, 301 Fisher Street, Keesler Air Force Base, MS 39534, USA

Correspondence should be addressed to Benjamin Smith, benjamin.smith.59@us.af.mil

Received 27 August 2012; Accepted 8 October 2012

Academic Editors: N. Martinez-Quiles, M. M. Nogueras, G. E. M. Reeves, and M. Trendelenburg

Copyright © 2012 B. Smith and M. B. Carroll. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 28-year-old healthy female presented to her primary care physician with lymphadenopathy, fatigue, malaise, and night sweats. Symptoms persisted despite conservative treatment and eventually the patient underwent multiple lymph node resections and a bone marrow biopsy before a diagnosis of IgG4-related disease (IgG4-RD) was made. IgG4-RD is a relatively new disorder first histopathologically recognized within the last decade. As the disease can affect a single organ or multiple organs, symptoms can vary greatly among patients. With symptoms ranging from mild, such as lower extremity edema, to severe, such as spinal cord compression, IgG4-RD must be considered in appropriate patients. Diagnostic criteria have been proposed based on organ involvement, serum IgG4 levels, and histopathological criteria. Diagnosis can be difficult to make with many studies suggesting different values for diagnostic criteria, such as the level of tissue IgG4+/IgG+ cell ratio to delineate IgG4-RD. Treatment consists of high dose glucocorticoids as a first line therapy with some patients choosing instead to simply undergo observation. This case illustrates the difficulty in diagnosis and the need for increased awareness among medical professionals.

1. Introduction

IgG4-RD is a relatively newly classified condition with unifying histopathologic features recognized only since the early 2000s [1]. The disorder is thought to mainly affect middle-aged to elderly men with a median age of onset of 58 years old [2, 3]. Exact incidence and prevalence are difficult to determine as many cases most likely go undiagnosed with limited awareness currently amongst medical professionals. Clinical findings vary by the organ system involved but many times are associated with tissue swelling or enlargement [1]. Due to the variety of clinical presentations, diagnosis can be delayed months to years and result in unnecessary tests and procedures.

2. Case Presentation

A 28-year-old female with no significant past medical history presented to her primary care physician with lymphadenopathy, night sweats, fatigue, and malaise. She was treated empirically and partially responded to a short course of glucocorticoids and an antibiotic. When initial laboratory workup was unrevealing for an obvious etiology and symptoms persisted, computed tomography (CT) of the neck and chest with contrast was performed that showed diffuse adenopathy (Figure 1) and hepatosplenomegaly. The patient was referred for lymph node resection that initially revealed only nonspecific B cell proliferation and did not support a specific etiology (Figure 2). With lymphoma a concern, she was referred to Hematology/Oncology for assessment. Hematology/Oncology evaluated the patient and performed a bone marrow biopsy which showed no cellular abnormalities consistent with lymphoma or leukemia. The patient’s symptoms then stabilized for several months.

However, when her symptoms again worsened, she was referred to Infectious Disease who entertained a broad differential including Kikuchi’s syndrome, Epstein-Barr virus (EBV), cytomegalovirus (CMV), toxoplasmosis, or human immunodeficiency virus (HIV) infection. Extensive serological testing was unrevealing and a second lymph node was removed, again without an obvious etiology. Rheumatology was then consulted and expanded the differential to include systemic lupus erythematosus, Sjögren’s syndrome, Castleman’s disease, autoimmune lymphoproliferative syndrome,
2 Case Reports in Immunology

Figure 1: CT neck with contrast revealed diffuse cervical adenopathy (arrows demonstrate lymphadenopathy).

Figure 2: Hematoxylin and eosin stain of a resected lymph node, 2x magnification. This preparation shows nonspecific reactive follicular hyperplasia (arrow demonstrates secondary follicle with prominent germinal center).

and IgG4-related disease (IgG4-RD). Table 1 highlights the various serologic and tissue examinations performed as a part of the workup for this patient. An additional lymph node was removed and sent to Pathology for IgG4 staining (Figure 3) which, in combination with the patient’s elevated serum IgG4 level of 206 mg/dL (normal 4–86 mg/dL), was very suspicious for IgG4-RD. Treatment modalities offered to the patient included a prolonged course of glucocorticoids or rituximab but she declined therapy as she and her spouse were attempting to conceive. The patient continues to attempt conception and therefore treatment has still not been initiated.

3. Diagnosis

The diagnosis of IgG4-RD can be difficult to make and misdiagnosis is common. One set of proposed diagnostic criteria as outlined in Table 2 calls for (1) organ enlargement, mass or nodular lesions, or organ dysfunction; (2) a serum IgG4 concentration >135 mg/dL; (3) histopathological findings of >10 IgG4 cells/high powered field (HPF) with an IgG4+/IgG+ cell ratio >40%. Based on these criteria a diagnosis is “definite” in patients who fulfill criteria (1), (2), and (3), “possible” if criteria (1) and (2) are met, and “probable” in patients with criteria (1) and (3) satisfied. The situations in which these criteria prove most difficult to utilize are in those from whom tissue cannot safely be obtained or it is very difficult to biopsy the involved organ, such as in pancreatic disease. When the diagnosis is in question, further clarification can be sought using organ specific criteria for IgG4-RD, such as in autoimmune pancreatitis, Mikulicz’s disease, and IgG4-related kidney disease. These additional organ-specific criteria greatly increase the specificity of the diagnostic criteria in applicable settings [2].

While the diagnostic criteria discussed earlier suggest an IgG4+/IgG+ cell ratio of >40%, other proposed diagnostic criteria recommend more stringent requirements such as a ratio of >50%. Others suggest that some cases of IgG4-RD may present with an even lower ratio such as >30% [1, 4]. A retrospective study performed by Masaki et al. looked at the various cutoffs and how this would alter the sensitivity and specificity of the diagnostic criteria, with results shown in Table 3.

Another aspect of the proposed diagnostic criteria state the serum IgG4 concentration should be >135 mg/dL. However, the serum IgG4 level can be misleading, with approximately 30% of patients with otherwise classic findings for this disease having normal serum IgG4 concentrations [1]. Conversely, the serum IgG4 level can be elevated in a variety of other unrelated conditions including primary sclerosing cholangitis, many forms of nonautoimmune pancreatitis, and atopic dermatitis. Even in the normal population, an elevated IgG4 level can be found in up to 5% of those tested [5].

Tissue biopsy and evaluation play a central role in diagnosis. Although IgG4-RD can manifest in nearly any organ system, it shares unique histologic findings regardless of location including dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, stromal fibrosis which is that of an irregularly whorled pattern, obliteratorive phlebitis, and an eosinophilic infiltrate [1, 6]. While the histology is characteristic, diagnosis requires specific immunohistochemical confirmation with IgG4 immunostaining. A finding of >10 IgG4 cells/HPF has benefits and shortcomings. In one study, setting the cutoff at >10 IgG4 cell/HPF provided 100% sensitivity but only 38.1% specificity [4]. Poor specificity has also been documented in various other studies that have revealed high numbers of IgG4 cells/HPF in other disease states, such as in cases of granulomatosis with polyangiitis [7].

Diagnosis can be difficult but the most important first step is a high clinical suspicion. This disease requires specific testing to be recognized and therefore must be sought out, not revealing itself on routine labs or biopsy. Furthermore, because of some shortcomings in the current diagnostic criteria, one must thoroughly consider other disorders in the differential diagnosis. In our case of unexplained generalized lymphadenopathy, fatigue, and night sweats, the differential
Table 1: Differential diagnosis with pertinent laboratory findings.

| Diagnosis                                      | Pertinent Laboratory Findings                                                                 |
|------------------------------------------------|-----------------------------------------------------------------------------------------------|
| **Lymphoma**                                   | Bone marrow and lymph node biopsy performed HTLV-1+2 antibodies (nonreactive)                  |
| **Castleman’s disease**                        | HHV-8 lymph node stains negative                                                               |
| **Autoimmune Lymphoproliferative syndrome**    | Less than 1.5% double negative (CD4−CD8−) T-cell count on cytometry                           |
| **Mycobacterial infection**                    | AFB culture of lymph node (negative)                                                           |
| **Systemic lupus erythematosus**                | ANA panel (1:160)                                                                             |
| **Viral infections**                           | Anti-dsDNA and anti-Sm antibodies (negative)                                                   |
| **Cat scratch disease**                        | Complement levels C3, C4 within normal range                                                   |
| **Sjögren’s syndrome**                         | EBV (nuclear Ag IgG positive, viral capsid IgG positive, viral capsid IgM negative),           |
| **Hepatitis**                                  | CMV (IgM negative, IgG negative), parvovirus B19 (IgM negative, IgG negative),               |
| **Cat scratch disease**                        | Hepatitis (HBs Ag negative, Hbc Ab negative, HBs Ab negative, HCV Ab negative)                |
| **Sjögren’s syndrome**                         | Bartonella panel (negative)                                                                    |

*HTLV-1+2: human T-lymphotropic virus type I and II, HHV-8: human herpes virus 8; AFB: acid-fast bacilli, ANA: antinuclear antibodies, Anti-dsDNA: antidi double-stranded DNA, Anti-Sm: anti-Smith; EBV = Epstein-Barr virus, CMV: cytomegalovirus, HBs Ag = hepatitis B surface antigen, and Hbc Ab: hepatitis B core antibody IgG, HBs Ab = hepatitis B surface antibody, HCV Ab: hepatitis C virus antibody, SSA: anti-Ro/SSA antibodies, and SSB: anti-La/SSB antibodies.

4. Treatment

Treatment strategies have not yet been validated by large randomized controlled trials. Recommendations are currently limited to case reports and consensus statements, with glucocorticoids considered first. Several glucocorticoid sparing regimens have also been suggested, with rituximab showing efficacy even in refractory disease [1, 6]. Treatment should include the input of the patient, as sometimes a watch-and-wait approach is sufficient depending on symptoms.
and organ involvement [1]. Regardless, patients should be monitored closely, because the disease process can progress and extensive fibrosis can occur making a treatment response less likely. Our patient chose a watch-and-wait approach as medication side effects were unacceptable to her and her husband as they were trying to conceive a child.

5. Conclusion

IgG4-RD is a new disease that has been present for many years but only better appreciated within the last decade. The currently proposed diagnostic criteria incorporate organ involvement, the serum IgG4 level, and tissue evaluation with IgG4+/IgG+ ratio and IgG4 cells/HPF. These criteria must be interpreted in the right clinical setting and diagnosis made only after a thorough consideration and exclusion of alternative diagnoses. Clinical features of the disease can be difficult to piece together given the wide variety of potential systems that can be involved and, therefore, the physician must have a high clinical suspicion. Treatment based on case reports and consensus consists mainly of glucocorticoids or similar agents that suppress lymphocytes. As the disease definition and our understanding of it continues to evolve, greater physician awareness is needed so that this diagnosis is not overlooked in future patients. Ongoing study of patient’s with IgG4-RD will provide a better understanding of this disorder, how to best approach treatment, and potentially a more refined diagnostic scheme.

Acknowledgments

The authors would like to thank Dr. Geoffrey Sasaki for his help in obtaining and interpreting the histopathology provided in the figures of this paper. The views expressed in this material are those of the authors and do not reflect the official policy or position of the US Government, the Department of Defense, or the Department of the Air Force.

References

[1] J. H. Stone, Y. Zen, and V. Deshpande, “Mechanisms of disease: IgG4-related disease,” The New England Journal of Medicine, vol. 366, no. 6, pp. 539–551, 2012.
[2] H. Umehara, K. Okazaki, Y. Masaki et al., “Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011,” Modern Rheumatology, vol. 22, no. 1, pp. 21–30, 2012.
[3] H. Umehara, K. Okazaki, Y. Masaki, M. Kawano, M. Yamamoto, T. Sacki et al., “A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details,” Modern Rheumatology, vol. 22, no. 1, pp. 1–14, 2011.
[4] Y. Masaki, N. Kurose, M. Yamamoto et al., “Cutoff values of serum IgG4 and histopathological IgG4+ plasma cells for diagnosis of patients with IgG4-related disease,” International Journal of Rheumatology, vol. 2012, Article ID 580814, 5 pages, 2012.
[5] J. H. Ryu, R. Horie, H. Sekiguchi, T. Peikert, and E. S. Yi, “Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice,” International Journal of Rheumatology, vol. 2012, Article ID 232960, 6 pages, 2012.
[6] M. N. Carruthers, J. H. Stone, and A. Khosroshahi, “The latest on IgG4-RD: a rapidly emerging disease,” Current Opinion in Rheumatology, vol. 24, no. 1, pp. 60–69, 2012.
[7] S. Y. Chang, K. Keogh, J. E. Lewis, J. H. Ryu, and E. S. Yi, “Increased IgG4-positive plasma cells in granulomatosis with polyangiitis: a diagnostic pitfall of IgG4-related disease,” International Journal of Rheumatology, vol. 2012, Article ID 121702, 6 pages, 2012.
[8] G. S. Kerr, A. Aggarwal, and S. McDonald-Pinkett, “A woman with rheumatoid arthritis, Sjögren’s syndrome, leg ulcer, and significant weight loss,” Arthritis Care & Research, vol. 64, no. 5, pp. 785–792, 2012.